Herpes zoster among persons living with HIV in the current antiretroviral therapy era
- PMID: 22766968
- PMCID: PMC4154488
- DOI: 10.1097/QAI.0b013e318266cd3c
Herpes zoster among persons living with HIV in the current antiretroviral therapy era
Abstract
Background: Previously, herpes zoster (HZ) was found to occur at a higher rate in the HIV population than the general population. However, there are limited data about the incidence, risk factors, and clinical outcomes of HZ in the current antiretroviral therapy (ART) era.
Methods: We identified HZ episodes in an urban HIV clinic cohort between 2002 and 2009. Three controls were matched to each case, and conditional logistic regression was used to assess for risk factors associated with incident HZ cases. Logistic regression was used to assess for factors associated with complicated HZ.
Results: One hundred eighty-three new HZ cases were identified in 4353 patients with 19,752 person-years (PY) of follow-up--an incidence rate 9.3/1000 PY. Cases were majority men (62%) and African American (75%), with a mean age of 39 years (interquartile range, 32-44 years). Fifty patients (28%) had complicated HZ with 12% developing postherpetic neuralgia. In multivariate regression, factors associated with the increased risk of HZ were having started ART within 90 days of the episode [adjusted odds ratio (AOR), 4.02; 95% confidence interval (CI), 1.31 to 12.41], having a viral load of >400 copies per milliliter (AOR, 1.49; 95% CI, 1.00 to 2.24), and having a CD4 <350 cells per cubic millimeter (AOR, 2.46; 95% CI, 1.42 to 4.23) or 350 to 500 cells per cubic millimeter (AOR, 2.02; 95% CI, 1.14 to 3.57) as compared with CD4 >500 cells per cubic millimeter.
Conclusions: The incidence of HZ is lower than previously reported in HIV cohorts but remains higher than the general population. Over one fourth of patients developed complicated HZ, which is remarkable given the young age of our population. Risk factors for HZ include markers of poor immune function, suggesting that appropriate ART may reduce the burden of HZ in this population.
Figures
Similar articles
-
The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era.J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):169-74. doi: 10.1097/01.qai.0000178408.62675.b0. J Acquir Immune Defic Syndr. 2005. PMID: 16186734
-
Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.Clin Infect Dis. 2015 Apr 15;60(8):1269-77. doi: 10.1093/cid/ciu1161. Epub 2015 Jan 18. Clin Infect Dis. 2015. PMID: 25601456
-
Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study.Int J STD AIDS. 2005 Oct;16(10):673-6. doi: 10.1258/095646205774357271. Int J STD AIDS. 2005. PMID: 16212714
-
Incidence of Herpes Zoster in HIV-Infected Patients Undergoing Antiretroviral Therapy: A Systematic Review and Meta-analysis.J Clin Med. 2021 May 25;10(11):2300. doi: 10.3390/jcm10112300. J Clin Med. 2021. PMID: 34070645 Free PMC article. Review.
-
Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis.Lancet HIV. 2020 Apr;7(4):e262-e278. doi: 10.1016/S2352-3018(19)30434-5. Epub 2020 Feb 25. Lancet HIV. 2020. PMID: 32109408
Cited by
-
Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States.Pharmacoecon Open. 2023 Nov;7(6):975-985. doi: 10.1007/s41669-023-00438-7. Epub 2023 Nov 2. Pharmacoecon Open. 2023. PMID: 37917310 Free PMC article.
-
Impact of Antiretroviral Therapy on the Risk of Herpes Zoster among Human Immunodeficiency Virus-Infected Individuals in Tanzania.Am J Trop Med Hyg. 2018 Feb;98(2):396-401. doi: 10.4269/ajtmh.17-0568. Epub 2018 Jan 4. Am J Trop Med Hyg. 2018. PMID: 29313475 Free PMC article.
-
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.Infect Dis Ther. 2017 Sep;6(3):333-361. doi: 10.1007/s40121-017-0165-y. Epub 2017 Aug 5. Infect Dis Ther. 2017. PMID: 28780736 Free PMC article. Review.
-
Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.Clin Infect Dis. 2020 Oct 23;71(7):e125-e134. doi: 10.1093/cid/ciz1090. Clin Infect Dis. 2020. PMID: 31677266 Free PMC article.
-
Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population.Pathogens. 2023 Feb 2;12(2):233. doi: 10.3390/pathogens12020233. Pathogens. 2023. PMID: 36839505 Free PMC article. Review.
References
-
- Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005 Jun 2;352(22):2271–84. - PubMed
-
- Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med. 2000 Mar 2;342(9):635–45. - PubMed
-
- Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):169–74. - PubMed
-
- Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 1995 Oct;9(10):1153–8. - PubMed
-
- Weller TH. Varicella and herpes zoster: A perspective and overview. J Infect Dis. 1992 Aug;166(Suppl 1):S1–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials